The new CADTH Post-Market Drug Evaluation (PMDE) Program will be launching a re-imagined evidence generation network in September 2022. The program will bring together an external network of Canada’s expert applied researchers, methodologists, and data analysts to provide evidence to answer questions posed by federal, provincial, and territorial decision-makers about post-market drug safety and effectiveness. As the network is being developed, the PMDE Program will be recruiting network partners.
For more detailed information on the program, please refer to the PMDE Program Overview.
Are you interested in joining the PMDE network to produce evidence for decision-makers? On February 1, 2022, CADTH issued its first request for proposal (RFP) for the PMDE network to identify core network partners to receive standing grant funding. On March 15, 2022, a second RFP to identify network contractors was issued.
If you have any questions about the PMDE Program’s upcoming launch, please email InfoPMDE@cadth.ca.
Post-market drug evaluation (PMDE) focuses on drugs that have proceeded through the approval process and are broadly available to patients and consumers. PMDE integrates health data and real-world evidence to inform decisions on drug safety and effectiveness and other key regulatory aspects.
The primary goal of the PMDE Program is to establish a network of applied researchers, analysts, and methodologists to answer queries related to post-market drug safety and effectiveness by bringing timely evidence into the hands of decision-makers through:
The PMDE Program will provide timely and reliable evidence to Canadian decision-makers including:
Core teams and contractors will be identified through a request for proposal (RFP) process starting in February 2022. For more information on the RFP, please visit our website to access the relevant PMDE RFP package specifically designed for grants and contracts. Alternatively, please contact InfoPMDE@cadth.ca.
For more information see the complete PMDE Program FAQs